Business Wire

TX-MAVENIR

14.12.2020 15:02:13 CET | Business Wire | Press release

Share
Mavenir and MTI Launch First Evenstar Remote Radio Head to Accelerate OpenRAN Adoption

Mavenir, the industry’s only end-to-end cloud-native network software provider for mobile operators, and Microelectronics Technology Inc. (MTI), a network solutions provider, announced today the general availability of the Evenstar B3 Remote Radio Head (RRH) in collaboration with Facebook Connectivity. The Evenstar B3 RRH will give mobile network operators (MNOs) the ability to accelerate the adoption of Open RAN technology by providing standardized architecture and a modular approach for disaggregated Radio Access Network (RAN) components.

Mavenir and MTI recently completed the end-to-end interoperability testing of the Evenstar B3 RRH and are now lab testing the solution with multiple MNOs around the world. The Evenstar B3 RRH from Mavenir and MTI not only addresses current feature requirements in networks today, but also provides flexibility for future feature upgrades, providing a true Virtualized RAN (vRAN) solution.

Launched earlier this year, the Evenstar program focuses on building general-purpose RAN reference architecture for 4G and 5G networks that are aligned with 3GPP and O-RAN specifications. The Evenstar program also contributes to the Telecom Infra Project (TIP)’s OpenRAN Project Group, working to accelerate the path to commercial deployment of simplified, flexible, disaggregated RAN technologies. RRHs, distribution units (DU), and control unit (CU) software have traditionally been only available as a packaged unit, limiting opportunities to serve suburban and rural locations. By decoupling these components, the Evenstar program enables MNOs to choose best-in-class technology and deploy solutions from an increasing number of technology partners.

“The availability of low cost RRHs based on OpenRAN specifications is key to faster adoption of OpenRAN. We are excited to work with Facebook, TIP and MTI to bring the first 4G/5G OpenRAN-compliant Evenstar radio to market that is generally available for use by the Open RAN community.” said Pardeep Kohli, President & CEO of Mavenir.

“MTI is excited to announce the general availability of the Evenstar RRH. This is a major milestone for MTI and for our partners in the Open RAN ecosystem. We will continue to introduce more products to the Open RAN market and address the needs of different regions.” said Allen Yen, Chairman & CEO of MTI.

The Evenstar B3 RRH is generally available now as part of the Evenstar program, with plans to expand into other Open RAN architectural elements. The Evenstar program will eventually include multiple RRH product SKUs, including FDD B3 (4T4R 4X40W). The RRH architecture is based on O-RAN Alliance Fronthaul specifications based on Split 7.2.

About MTI

Microelectronics Technology Inc. (MTI) is a high-technology company that has specialized in wireless communication product development, manufacturing, and global sales for more than 35 years. Based on core competency in RF/ Microwave, MTI has established a leading position in the fields of Remote Radio Heads, Microwave Radios, Satellite Transceivers and ODUs, Broadband Wireless access products, and Radio Frequency Identification (RFID) readers and modules. With this excellent record of accomplishment, MTI has established valued, long-term partnerships with world-leading partners. MTI now offers a portfolio of products that are O-RAN compliant. For more information, visit: www.mtigroup.com

About Mavenir

Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers.

Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. For more information, visit: www.mavenir.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye